MAIA Biotechnology Reports Updates on Disease Control Rates for THIO-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
MAIA Biotechnology, Inc. (NYSE:MAIA) has announced updates on disease control data for its ongoing THIO-101 phase 2 trial for advanced Non-Small Cell Lung Cancer (NSCLC). Of the first 11 patients enrolled, 9 (82%) met the primary endpoint of disease control. All patients have previously failed 2 or more prior lines of treatment including an immune checkpoint inhibitor and platinum-based chemotherapy for advanced NSCLC.
July 11, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MAIA Biotechnology's ongoing THIO-101 phase 2 trial for advanced NSCLC shows promising results with 82% of patients meeting the primary endpoint of disease control. This could potentially boost investor confidence in the company.
The positive results from the THIO-101 phase 2 trial indicate that the drug is effective in controlling advanced NSCLC. This could potentially lead to increased investor confidence in MAIA Biotechnology, which could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100